Intestinal bacterial microflora - A potential source of chronic inflammation in patients with chronic kidney disease

Nephrology Dialysis Transplantation

Volumn 21, Issue 8, 2006, Pages 2057-2060

  Kotanko, Peter ^a   Carter, Mary ^a   Levin, Nathan W ^a  

^a RENAL RESEARCH INSTITUTE   (United States)

Author keywords

Bacterial translocation; Chronic inflammation; Chronic kidney disease; Gut; Intestinal microflora

Indexed keywords

DEFERIPRONE; DIURETIC AGENT; IRON; IRON CHELATING AGENT; PROBIOTIC AGENT;

BACTERIAL COUNT; BACTERIAL GROWTH; BACTERIAL INFECTION; BACTERIAL METABOLISM; BACTERIAL OVERGROWTH; BACTERIAL TRANSLOCATION; BACTERIAL VIRULENCE; CHRONIC INFLAMMATION; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONSTIPATION; DISEASE PREDISPOSITION; EDEMA; HEMODIALYSIS PATIENT; HUMAN; INFECTION RISK; INTESTINE FLORA; INTESTINE MUCOSA PERMEABILITY; IRON BLOOD LEVEL; IRON METABOLISM; IRON OVERLOAD; IRON THERAPY; MALNUTRITION; NONHUMAN; NOTE; PRIORITY JOURNAL; RISK ASSESSMENT; UREMIA;

ANIMALS; BACTERIA; BACTERIAL PHYSIOLOGICAL PHENOMENA; BACTERIAL PHYSIOLOGY; BACTERIAL TRANSLOCATION; CHRONIC DISEASE; CYTOKINES; DIURETICS; FERMENTATION; HUMANS; INFLAMMATION; INTESTINAL ABSORPTION; INTESTINES; IRON; IRON CHELATING AGENTS; KIDNEY DISEASES; PROBIOTICS; RATS; REACTIVE OXYGEN SPECIES; UREMIA; XANTHINE OXIDASE;

EID: 33748086020     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfl281     Document Type: Note

References (28)

1. Yao Q, Axelsson J, Heimburger O et al. Systemic inflammation in dialysis patients with end-stage renal disease: Causes and consequences. Minerva Urol Nefrol 2004; 56: 237-248
2. Ding LA, Li JS. Gut in diseases: Physiological elements and their clinical significance. World J Gastroenterol 2003; 9: 2385-2389
3. Eckburg PB, Bik EM, Bernstein CN et al. Diversity of the human intestinal microbial flora. Science 2005; 308: 1635-1638
4. Williamson RC. Intestinal adaptation (first of two parts). Structural, functional and cytokinetic changes. N Engl J Med 1978; 298: 1393-1402
5. Baumgart DC, Dignass AU. Intestinal barrier function. Curr Opin Clin Nutr Metab Care 2002; 5: 685-694
6. Niebauer J, Volk HD, Kemp M et al. Endotoxin and immune activation in chronic heart failure: A prospective cohort study. Lancet 1999; 353: 1838-1842
7. MacFie J. Current status of bacterial translocation as a cause of surgical sepsis. Br Med Bull 2004; 71: 1-11
8. Green BT, Lyte M, Chen C et al. Adrenergic modulation of Escherichia coli O157:H7 adherence to the colonic mucosa. Am J Physiol Gastrointest Liver Physiol 2004; 287: G1238-1246
9. Schreiber KL, Brown DR. Adrenocorticotrophic hormone modulates Escherichia coli O157:H7 adherence to porcine colonic mucosa. Stress 2005; 8: 185-190
10. Schimpl G, Pabst MA, Feierl G et al. A tungsten supplemented diet attenuates bacterial translocation in chronic portal hypertensive and cholestatic rats: Role of xanthine dehydrogenase and xanthine oxidase. Gut 1999; 45: 904-910
11. Weber-Mzell D, Zaupa P, Petnehazy T et al. The role of nuclear factor-kappa B in bacterial translocation in cholestatic rats. Pediatr Surg Int 2006; 22: 43-49
12. Simenhoff ML, Saukkonen JJ, Burke JF et al. Bacterial populations of the small intestine in uremia. Nephron 1978; 22: 63-68
13. Bammens B, Evenepoel P, Keuleers H et al. Free serum concentrations of the protein-bound retention solute p-cresol predict mortality in hemodialysis patients. Kidney Int 2006; 69: 1081-1087
14. Magnusson M, Magnusson KE, Sundqvist T et al. Increased intestinal permeability to differently sized polyethylene glycols in uremic rats: effects of low- and high-protein diets. Nephron 1990; 56: 306-311
15. Magnusson M, Magnusson KE, Sundqvist T et al. Impaired intestinal barrier function measured by differently sized polyethylene glycols in patients with chronic renal failure. Gut 1991; 32: 754-759
16. Kang JY. The gastrointestinal tract in uremia. Dig Dis Sci 1993; 38: 257-268
17. de Almeida Duarte JB, de Aguilar-Nascimento JE, Nascimento M et al. Bacterial translocation in experimental uremia. Urol Res 2004; 32: 266-270
18. Wandersman C, Delepelaire P. Bacterial iron sources: From siderophores to hemophores. Annu Rev Microbiol 2004; 58: 611-647
19. Walter T, Olivares M, Pizarro F et al. Iron, anemia, and infection. Nutr Rev 1997; 55: 111-124
20. Ashrafian H. Hepcidin: The missing link between hemochromatosis and infections. Infect Immun 2003; 71: 6693-6700
21. Oppenheimer SJ. Iron and its relation to immunity and infectious disease. J Nutr 2001; 131: 616S-633S.
22. Canziani ME, Yumiya ST, Rangel EB et al. Risk of bacterial infection in patients under intravenous iron theraphy: Dose versus length of treatment. Artif Organs 2001; 25: 866-869
23. Brissot P, Bolder U, Schteingart CD et al. Intestinal absorption and enterohepatic cycling of biliary iron originating from plasma non-transferrin-bound iron in rats. Hepatology 1997; 25: 1457-1461
24. Robson KJ. Hepcidin and its role in iron absorption. Gut 2004; 53: 617-619
25. Lund EK, Wharf SG, Fairweather-Tait SJ et al. Oral ferrous sulfate supplements increase the free radical-generating capacity of feces from healthy volunteers. Am J Clin Nutr 1999; 69: 250-255
26. Duggan C, Gannon J, Walker WA. Protective nutrients and functional foods for the gastrointestinal tract. Am J Clin Nutr 2002; 75: 789-808
27. Ranganathan N, Patel BG, Ranganathan P et al. In vitro and in vivo assessment of intraintestinal bacteriotherapy in chronic kidney disease. Asaio J 2006; 52: 70-79
28. Smith D, Spanel P. Selected ion flow tube mass spectrometry (SIFT-MS) for on-line trace gas analysis. Mass Spectrom Rev 2005; 24: 661-700